Could Low Float Nasdaq Profile (IMMX) Be Lined Up For Near Term Vertical Surge After Yesterday's Huge News?
Yahoo Finance Reports IMMX To Have A Float Of 1.29Mn!
IMMX is trending green and requires immediate attention.
Yesterday, the company made a potential game-changing announcement.
Check it out:
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
LOS ANGELES, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. Historically, 43-67% of patients have completed planned treatment cycles with approved dr-ugs used to treat soft tissue sarcoma (STS) according to Demetri et al., 2016, and Schöffski et al., 2016. Completion of planned treatment cycles refers to lack of dr-ug-related interruptions (cycle delays, dose reductions, or dose interruptions due to dr-ug toxicity).
“With standard treatments widely used today, cancer patients face a long list of dr-ug-related debilitating side-effects that cause treatment delays, dose reductions, or dose interruptions due to toxicity, interfering with the ability to treat them effectively,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “In this interim clinical trial update, we are thrilled to report that IMX-110 has been well tolerated. We believe that IMX-110 could become a potentially attractive option to improve the patient experience in oncology in the future.”
Read the full article here.
Now, there isn't a ton of technical info out there on IMMX, but I can tell you this.
Currently, this profile is trading above a couple lines of potential support including its:
- 13-Day Exponential Moving Average
- 20-Day Simple Moving Average
Plus, you need to remember this is a low float profile which means volatility can crop up at any moment on a daily basis.
You'll need to watch this low float Nasdaq idea closely today.
If you haven't yet, read my initial report below and get IMMX on your radar now.
Listen. There's no time to mess around.
The markets have been taking a beating recently, but that doesn't mean we haven't been able to uncover under-the-radar hidden gems with serious upside potential.
In case you missed it, I brought a breakout idea to your attention first thing Tuesday morning in (DATS).
This low float Nasdaq profile came out of the opening bell with a head full of steam.
Opening at $2.46, DATS ran over $1.00+ to a high of $3.82 on the session Tuesday for an incredible intraday surge of 55% (approx.).
At the same time that DATS was making headlines, I was tracking another Nasdaq idea with a ton of upside potential based on several potential catalysts.
For Thursday, January 20th, Nasdaq biopharma company Immix Biopharma, Inc. (IMMX) requires immediate attention.
ImmixBio™ is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases.
Their proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ Platform produces dr-ugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines.
The company's TME Normalization™ Technology allows their dr-ug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME.
They've uncovered fundamental biological systems that link oncology and immuno-dysregulated diseases. In addition to oncology, the company's pipeline includes Tissue-Specific Biologic™ candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
And right now, this Nasdaq profile has multiple potential catalysts that could lead it to a near term breakout.
Nasdaq Profile (IMMX) - 4 Potential Catalysts Lead The Way
No 1. - U.S. FDA Grants (RPD) Designation For IMX-110
No 2. - A Crazy Low Float
No 3. - Positive Results Thrill CEO
No 4. - IPO And Joining The NasdaqCM
But more on those in a second...
*IMMX's Insanely Huge Market Opportunities* (1)
STS is a rare cancer that begins in the tissues that connect, support, and surround the body structures. These tissues include muscle, fat, blood vessels, tendons, nerves and joint linings. The global STS market is estimated to reach approximately $6.5Bn by 2030 from the estimated $2.9Bn in 2019. Globally, there are roughly 116,000 new cases of STSs each year, of which 21,500 are in the European Union and 40,500 are in China. According to the American Cancer Society, there were roughly 13,000 new cases of STS in the United States during 2020. Approximately 160,000 people live with soft tissue cancers in the United States.
Colorectal cancers are cancers that arise from the colon, rectum and anus. The colorectal cancer market is estimated to reach approximately $31.2Bn by 2025 from the estimated $26.3Bn in 2019. According to the American Cancer Society, there were roughly 149,500 new cases of colorectal cancer in the United States. Globally, there are roughly 1,930,000 new cases of colorectal cancer each year, of which 519,500 are in Europe, 148,500 are in Japan, 20,500 are in Australia and New Zealand, and 555,000 are in China.
Inflammatory bowel disease is a complex disease with many contributing factors, primarily caused by an overactive immune system. Ulcerative colitis and Crohn’s disease are two of the most common forms of inflammatory bowel disease. The inflammatory bowel disease market is expected to reach $21.4Bn by 2024 from the existing $18.4Bn in 2019. Inflammatory bowel disease is estimated to affect over 2,000,000 people in the United States and over 5,000,000 people globally.
IMMX Could Have New First-Line Therapy for STS
At the moment, current cancer treatment approaches are generally either cytotoxic chemotherapies or focus on targeting one single receptor or one single mutation, which limits their ability to counter an evolvable tumor and its micro-environment. (2)
With its Tissue-Specific Therapeutic IMX-110 treatment, the company believes it may have first-line therapy for STS and multiple other solid tumors, improving tolerability and progression free survival, while providing an alternative to conventional doxorubicin, a current first-line therapy initially approved for medical use in the United States in 1974. (1)